Vestfold Hospital Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2011
NCT01022983
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Vestfold Hospital trust, Norway

Active Ingredients

Drugs in Phase 4 Trials (1)

levosimendan (1 trial)

Drugs in Phase 2 Trials (1)

rimabotulinumtoxinB (Myobloc) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 4)

Hip Fractures (Phase 4)

Urinary Bladder, Overactive (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2